IP Library › Granted Patent US 12,276,671
Granted Patent B2
US 12,276,671 · App. 18/599,751 · Granted Apr 15, 2025

Phospho-TAU antibodies and methods of use

Inventors: Andreas Jeromin (Alachua, FL); Krish Venkat (Lawrenceville, NJ)
Assignee: ALZPATH, INC.
G01N33/6896C07K16/18G01N33/53G01N33/6857C07K2317/20C07K2317/24C07K2317/52C07K2317/565G01N2333/4704G01N2333/4709G01N2333/96416G01N2800/2821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,276,671
App. No.
18/599,751
Granted
Apr 15, 2025
Kind
B2
Abstract

Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.

Claims (80)

1. A method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), wherein:

(a) the VH comprises SEQ ID NO: 31 and the VL comprises SEQ ID NO: 36;

(b) the VH comprises SEQ ID NO: 33 and the VL comprises SEQ ID NO: 39;

(c) the VH domain comprises SEQ ID NO: 34 and the VL comprises SEQ ID NO: 40;

(d) the VH domain comprises SEQ ID NO: 30 and the VL comprises SEQ ID NO: 35;

(e) the VH domain comprises SEQ ID NO: 31 and the VL comprises SEQ ID NO: 37; or

(f) the VH domain comprises SEQ ID NO: 32 and the VL comprises SEQ ID NO: 38.

2. A method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL),

wherein the VH comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 30-34, and wherein the VL comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOS: 35-40; and

wherein the VH comprises a HCDR1 sequence, a HCDR2 sequence, and a HCDR3 sequence, and the VL comprises a LCDR1 sequence, a LCDR2 sequence, and a LCDR3 sequence, wherein:

(a) the HCDR1 sequence comprises SEQ ID NO: 2, the HCDR2 sequence comprises SEQ ID NO: 7, the HCDR3 sequence comprises SEQ ID NO: 11, the LCDR1 sequence comprises SEQ ID NO: 15, the LCDR2 sequence comprises SEQ ID NO: 21, and the LCDR3 sequence comprises SEQ ID NO: 25;

(b) the HCDR1 sequence comprises SEQ ID NO: 4, the HCDR2 sequence comprises SEQ ID NO: 7, the HCDR3 sequence comprises SEQ ID NO: 12, the LCDR1 sequence comprises SEQ ID NO: 18, the LCDR2 sequence comprises SEQ ID NO: 23, and the LCDR3 sequence comprises SEQ ID NO: 28;

(c) the HCDR1 sequence comprises SEQ ID NO: 5, the HCDR2 sequence comprises SEQ ID NO: 9, the HCDR3 sequence comprises SEQ ID NO: 13, the LCDR1 sequence comprises SEQ ID NO: 19, the LCDR2 sequence comprises SEQ ID NO: 21, and the LCDR3 sequence comprises SEQ ID NO: 29;

(d) the HCDR1 sequence comprises SEQ ID NO: 1, the HCDR2 sequence comprises SEQ ID NO: 6, the HCDR3 sequence comprises SEQ ID NO: 10, the LCDR1 sequence comprises SEQ ID NO: 14, the LCDR2 sequence comprises SEQ ID NO: 20, and the LCDR3 sequence comprises SEQ ID NO: 24;

(e) the HCDR1 sequence comprises SEQ ID NO: 2, the HCDR2 sequence comprises SEQ ID NO: 7, the HCDR3 sequence comprises SEQ ID NO: 11, the LCDR1 sequence comprises SEQ ID NO: 16, the LCDR2 sequence comprises SEQ ID NO: 22, and the LCDR3 sequence comprises SEQ ID NO: 26; or

(f) wherein the HCDR1 sequence comprises SEQ ID NO: 3, the HCDR2 sequence comprises SEQ ID NO: 8, the HCDR3 sequence comprises SEQ ID NO: 10, the LCDR1 sequence comprises SEQ ID NO: 17, the LCDR2 sequence comprises SEQ ID NO: 20, and the LCDR3 sequence comprises SEQ ID NO: 27.

3. A method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody comprising a heavy chain and a light chain, wherein:

(a) the heavy chain comprises SEQ ID NO: 43 and the light chain comprises SEQ ID NO: 44;

(b) the heavy chain comprises SEQ ID NO: 48 and the light chain comprises SEQ ID NO: 49;

(c) the heavy chain comprises SEQ ID NO: 50 and the light chain comprises SEQ ID NO: 51;

(d) the heavy chain comprises SEQ ID NO: 41 and the light chain comprises SEQ ID NO: 42;

(e) the heavy chain comprises SEQ ID NO: 43 and the light chain comprises SEQ ID NO: 45; or

(f) the heavy chain comprises SEQ ID NO: 46 and the light chain comprises SEQ ID NO: 47.

4. The method of claim 2 , wherein the phosphorylated tau is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

5. The method of claim 2 , wherein the phosphorylated tau is pTau-181, pTau-217, or pTau-231.

6. The method of claim 2 , wherein the antibody is a monoclonal antibody.

7. The method of claim 2 , wherein the antibody is a rabbit monoclonal antibody.

8. The method of claim 2 , wherein the antibody is a chimeric antibody or antigen binding fragment thereof.

9. The method of claim 2 , wherein the antibody comprises an IgG1 constant region.

10. The method of claim 2 , wherein the sample is selected from the group consisting of a blood sample, a plasma sample, a serum sample, and a cerebrospinal fluid (CSF) sample.

11. The method of claim 2 , further comprising:

detecting the antibody or antibody fragment bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing Alzheimer's disease in the individual based on the phosphorylated tau that is detected.

12. The method of claim 2 , further comprising:

detecting the antibody or antibody fragment bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing a prognosis of the individual for developing Alzheimer's disease based on the phosphorylated tau that is detected.

13. The method of claim 2 , further comprising determining the individual's age, genotype, or expression of a biomarker.

14. The method of claim 13 , wherein the biomarker is selected from the group consisting of Aβ42, Aβ40, Aβ38, BACE1, hFABP, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, alpha-synuclein, TDP-43, ferritin, VILIP-1, NfL, GFAP, and combinations thereof.

15. The method of claim 12 , wherein the method has a specificity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

16. The method of claim 12 , wherein the method has a sensitivity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

17. The method of claim 2 , wherein the method is performed in vitro.

18. The method of claim 2 , wherein the phosphorylated tau is pTau-217.

19. The method of claim 1 , wherein the phosphorylated tau is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

20. The method of claim 1 , wherein the phosphorylated tau is pTau-181, pTau-217, or pTau-231.

21. The method of claim 1 , wherein the phosphorylated tau is pTau-217.

22. The method of claim 1 , wherein the antibody is a monoclonal antibody.

23. The method of claim 1 , wherein the antibody is a rabbit monoclonal antibody.

24. The method of claim 1 , wherein the antibody is a chimeric antibody or antigen binding fragment thereof.

25. The method of claim 1 , wherein the antibody comprises an IgG1 constant region.

26. The method of claim 1 , wherein the sample is selected from the group consisting of a blood sample, a plasma sample, a serum sample, and a cerebrospinal fluid (CSF) sample.

27. The method of claim 1 , further comprising:

detecting the antibody or antibody fragment bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing Alzheimer's disease in the individual based on the phosphorylated tau that is detected.

28. The method of claim 1 , further comprising:

detecting the antibody or antibody fragment bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing a prognosis of the individual for developing Alzheimer's disease based on the phosphorylated tau that is detected.

29. The method of claim 1 , further comprising determining the individual's age, genotype, or expression of a biomarker.

30. The method of claim 29 , wherein the biomarker is selected from the group consisting of Aβ42, Aβ40, Aβ38, BACE1, hFABP, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, alpha-synuclein, TDP-43, ferritin, VILIP-1, NfL, GFAP, and combinations thereof.

31. The method of claim 28 , wherein the method has a specificity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

32. The method of claim 28 , wherein the method has a sensitivity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

33. The method of claim 1 , wherein the method is performed in vitro.

34. The method of claim 3 , wherein the phosphorylated tau is selected from the group consisting of pTau-181, pTau-212, pTau-217, pTau-231, pTau-214, and pTau-220.

35. The method of claim 3 , wherein the phosphorylated tau is pTau-181, pTau-217, or pTau-231.

36. The method of claim 3 , wherein the phosphorylated tau is pTau-217.

37. The method of claim 3 , wherein the antibody is a monoclonal antibody.

38. The method of claim 3 , wherein the antibody is a rabbit monoclonal antibody.

39. The method of claim 3 , wherein the antibody is a chimeric antibody.

40. The method of claim 3 , wherein the antibody comprises an IgG1 constant region.

41. The method of claim 3 , wherein the sample is selected from the group consisting of a blood sample, a plasma sample, a serum sample, and a cerebrospinal fluid (CSF) sample.

42. The method of claim 3 , further comprising:

detecting the antibody bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing Alzheimer's disease in the individual based on the phosphorylated tau that is detected.

43. The method of claim 3 , further comprising:

detecting the antibody bound to the phosphorylated tau, thereby detecting the phosphorylated tau in the sample; and

establishing a prognosis of the individual for developing Alzheimer's disease based on the phosphorylated tau that is detected.

44. The method of claim 3 , further comprising determining the individual's age, genotype, or expression of a biomarker.

45. The method of claim 44 , wherein the biomarker is selected from the group consisting of Aβ42, Aβ40, Aβ38, BACE1, hFABP, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, alpha-synuclein, TDP-43, ferritin, VILIP-1, NfL, GFAP, and combinations thereof.

46. The method of claim 43 , wherein the method has a specificity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

47. The method of claim 43 , wherein the method has a sensitivity of at least about 85% for differentiating the Alzheimer's disease in the individual from a normal control based on the phosphorylated tau that is detected.

48. The method of claim 3 , wherein the method is performed in vitro.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2024
From: JEROMIN, ANDREAS; VENKAT, ANNA
To: ALZPATH, INC.
Reel/Frame 066774/0463 →
Continuity (3)
Continuation PCTUS2022042963 · Sep 8, 2022
Provisional Application 63242437 · Sep 9, 2021
Related Publication 20240353428A1 · Oct 24, 2024
References Cited (92)
US 4694778A · Learn et al. · 1987 [cited by applicant]
US 9371376B2 · Alderfer et al. · 2016 [cited by applicant]
US 9447179B2 · Winderickx et al. · 2016 [cited by applicant]
US 10393759B2 · Wilson et al. · 2019 [cited by applicant]
US 11275092B2 · Wilson et al. · 2022 [cited by applicant]
US 20040219509A1 · Valkirs et al. · 2004 [cited by applicant]
US 20050260697A1 · Wang et al. · 2005 [cited by applicant]
US 20050272110A1 · Drukier · 2005 [cited by applicant]
US 20090159812A1 · Livingston · 2009 [cited by applicant]
US 20110003707A1 · Goix et al. · 2011 [cited by applicant]
US 20140094386A1 · Wilson et al. · 2014 [cited by applicant]
US 20160376351A1 · Adolfsson · 2016 [cited by examiner]
US 20170082641A1 · Rhyne et al. · 2017 [cited by applicant]
US 20170106084A1 · Bader · 2017 [cited by examiner]
US 20170137502A1 · Pfeifer et al. · 2017 [cited by applicant]
US 20180080945A1 · Goetzl · 2018 [cited by examiner]
US 20180238910A1 · Kang et al. · 2018 [cited by applicant]
US 20180321261A1 · Stanley · 2018 [cited by applicant]
US 20190033328A1 · Tokuda et al. · 2019 [cited by applicant]
US 20190169275A1 · Griswold-Prenner et al. · 2019 [cited by applicant]
US 20200377609A1 · Sievers et al. · 2020 [cited by applicant]
US 20220018856A1 · Jannes et al. · 2022 [cited by applicant]
US 20220146535A1 · Chai et al. · 2022 [cited by applicant]
US 20220229074A1 · Wilson et al. · 2022 [cited by applicant]
US 20220244276A1 · Wilson et al. · 2022 [cited by applicant]
US 20240360206A1 · Jeromin et al. · 2024 [cited by applicant]
WO WO2010011506A2 · 2010 [cited by applicant]
WO WO2019085804A1 · 2019 [cited by applicant]
WO WO2019094595A2 · 2019 [cited by applicant]
WO WO2021178545A1 · 2021 [cited by applicant]
WO WO2022115705A2 · 2022 [cited by applicant]
WO WO2022150735A1 · 2022 [cited by applicant]
WO WO2023039107A2 · 2023 [cited by applicant]
WO WO2024192404A1 · 2024 [cited by applicant]
Kipriyanov et al., Mol Biotechnol. Jan. 2004;26(1):39-60. doi: 10.1385/MB:26:1:39. PMID: 14734823. [cited by examiner]
Wegmann et al., Curr Opin Neurobiol. Aug. 2021;69:131-138. doi: 10.1016/j.conb.2021.03.003. Epub Apr. 21, 2021. PMID: 33892381. [cited by examiner]
Janeway et al., Immunobiology, 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by examiner]
Rudikoff et al., Proc Natl Acad Sci USA. Mar. 1982;79(6):1979-83. [cited by examiner]
Edwards et al., J Mol Biol. Nov. 14, 2003;334(1): 103-18. [cited by examiner]
Goel et al., J Immunol. Dec. 15, 2004; 173(12):7358-67. [cited by examiner]
Llyod et al., Protein Eng Des Sel. Mar. 2009;22(3):159-68. doi: 10.1093/protein/gzn058. Epub Oct. 29, 2008. [cited by examiner]
Lescar, et al. Journal of Biological Chemistry 270.30 (1995): 18067-18076. [cited by examiner]
Kanyavuz et al., Nat Rev Immunol. Jun. 2019; 19(6):355-368. doi: 10.1038/S41577-019-0126-7. [cited by examiner]
Al-Lazikani, Bissan, et al. Standard Conformations for the Canonical Structures of Immunoglobulins. Journal of Molecular Biology, vol. 273, 927-948 (1997). [cited by applicant]
Bird, Robert E., et al. Single-chain Antigen-Binding Proteins. Science, vol. 242, 423-426 (1988). [cited by applicant]
Clackson, Tim, et al. Making antibody fragments using phage display libraries. Nature, vol. 352, 624-628 (1991). [cited by applicant]
Colbere-Garapin, Florence, et al. A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells. Journal of Molecular Biology, vol. 150, 1-14 (1981). [cited by applicant]
Cole, S.P.C., et al. The EBV-Hybridoma Technique and its Application to Human Lung Cancer. Monoclonal Antibodies and Cancer Therapy, vol. 27, 77-96 (1985). [cited by applicant]
Courtenay-Luck, N S. Genetic Manipulation of Monoclonal Antibodies. Monoclonal Antibodies: Production, Engineering and Clinical Application, Chapter 8, 166-179 (1995). [cited by applicant]
Crouse, Gray F., et al. Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes. Molecular Cell Biology, vol. 3, 257-266 (1983). [cited by applicant]
Cummings, Jeffrey, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimer's & Dementia, Translational Research & Clinical Interventions, vol. 8, 1-24 (2022). [cited by applicant]
Goldspiel, Barry R., et al. Human Gene Therapy. Clinical Pharmacy, vol. 12, 488-505 (1993). [cited by applicant]
Hanes, Jozef, et al. In Vitro Selection and Evolution of Functional Proteins by Using Ribosome Display. PNAS USA, vol. 94, 4937-4942 (1997). [cited by applicant]
Honegger, Annemarie, et al. Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool. Journal of Molecular Biology, vol. 309, 657-670 (2001). [cited by applicant]
Huse, William D., et al. Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda. Science, vol. 246, 1275-1281 (1989). [cited by applicant]
Huston, James S., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Huston, James S, et al. Protein Engineering of Single-chain Fv Analogs and Fusion Proteins. Methods in Enzymology, vol. 203, 46-96 (1991). [cited by applicant]
Kabat, Elvin A., et al. Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, T-Cell Receptors for Antigen, T-Cell Surface Antigens, β [cited by applicant]
Köhler, G., et al. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity. Nature, vol. 256, 495-497 (1975). [cited by applicant]
Kozbor, Danuta, et al. The production of monoclonal antibodies from human lymphocytes. Immunology Today, vol. 4, No. 3, 72-79 (1983). [cited by applicant]
Kutemeier, G., et al. Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-round PCR. Biotechniques, vol. 17, 242-246 (1994). [cited by applicant]
Larrick, James W, et al. PCR Amplification of Antibody Genes. Methods: A Companion to Methods in Enzymology, vol. 2, No. 2, 106-110 (1991). [cited by applicant]
Lefranc, Marie-Paule. The IMGT Unique Numbering for Immunoglobulins. T-Cell Receptors and Ig-Like Domains. The Immunologist, vol. 7, 132-136 (1999). [cited by applicant]
Lowy, Israel, et al. Isolation of Transforming DNA: Cloning the Hamster aprt Gene. Cell, vol. 22, 817-823 (1980). [cited by applicant]
MacCallum, Robert M., et al. Antibody-antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology, vol. 262, 732-745 (1996). [cited by applicant]
Mielke, Michelle M., Ph.D., et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, vol. 7… [cited by applicant]
Morgan, Richard A., et al. Human Gene Therapy. Annual Review of Biochemistry, vol. 62, 191-217 (1993). [cited by applicant]
Morrison, Sherie L., et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of Sciences of the United States of America, Immunolog… [cited by applicant]
Mulligan, R.C., et al. Selection for animal cells that express the [cited by applicant]
Mulligan, Richard C. The Basic Science of Gene Therapy. Science, vol. 260, 926-932 (1993). [cited by applicant]
Neuberger, Michael S., et al. Recombinant antibodies possessing novel effector functions. Nature, vol. 312, 604-608 (1984). [cited by applicant]
O'Hare, K., et al. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proceedings of the National Academy of Sciences of the United … [cited by applicant]
PCT/US2022/042963 International Search Report and Written Opinion dated Jun. 14, 2023. [cited by applicant]
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure. Retrieved from internet on Apr. 2, 2024: https://www.businesswire.com/news/home/20240321224578/en/Quanter… [cited by applicant]
Santerre, Robert F., et al. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene, vol. 30, 147-156 (1984). [cited by applicant]
Skerra, Arne, et al. Assembly of a Functional Immunoglobulin Fv Fragment in [cited by applicant]
Szybalska, Elizabeth H., et al. Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait. Proceedings of the National Academy of Sciences of the United States of America, Genetics, … [cited by applicant]
Takeda, Shun-Ichi, et al. Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature, vol. 314, 452-454 (1985). [cited by applicant]
Tolstoshev, Paul. Gene Therapy, Concepts, Current Trials and Future Directions. Annual Review Pharmacology and Toxicology, vol. 32, 573-596 (1993). [cited by applicant]
Ward, E. Sally, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Ward, E. Sally, et al., Genetic Manipulation and Expression of Antibodies. Monoclonal Antibodies: Principles and Applications, Wiley-Liss Inc., 137-185 (1995). [cited by applicant]
Whitelegg, Nicholas R. J., et al. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Engineering, vol. 13, 819-824 (2000). [cited by applicant]
Wigler, Michael, et al. Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. Cell, vol. 11, 223-232 (1977). [cited by applicant]
Wigler, Michael, et al. Transformation of mammalian cells with an amplifiable dominant-acting gene. Proceedings of the National Academy of Sciences of the United States of America, Genetics, vol. 77, 3567-3570 (1980). [cited by applicant]
Wu, George Y., et al. Delivery systems for gene therapy. Biotherapy, vol. 3, 87-95 (1991). [cited by applicant]
Hampel, Harald et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. Jan. 2010;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub Oct. 22, 2009. [cited by applicant]
Jonaitis, Erin M. et al. Plasma phosphorylated tau 217 in preclinical Alzheimer's disease. Brain Commun. Mar. 6, 2023;5(2):fcad057. doi: 10.1093/braincomms/fcad057. eCollection 2023. [cited by applicant]
Mintun, M. et al., Donanumab in Early Alzheimer's Disease, N Engl J Med, 2021, vol. 384, No. 18, pp. 1691-1704. [cited by applicant]
Neddens, Joerg et al. Phosphorylation of different tau sites during progression of Alzheimer's disease. Acta Neuropathol Commun. Jun. 29, 2018;6(1):52. doi: 10.1186/s40478-018-0557-6. [cited by applicant]
PCT/US2024/020266 International Search Report and Written Opinion dated Jul. 8, 2024. [cited by applicant]
Pontecorvo, M. et al., Association of Donanemab Treatment with Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease, JAMA Neurology, 2022, vol. 79, No. 12, pp. 1250-1259. [cited by applicant]
U.S. Appl. No. 18/770,102 Office Action dated Nov. 18, 2024. [cited by applicant]